Dyslipidemia and glucose dysregulation in overweight and obese patients

Clinical Cornerstone

Volumn 8, Issue 3, 2007, Pages 38-52

  LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOCANNABINOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

ADIPOSE TISSUE; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIETARY INTAKE; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; FOOD INTAKE; HUMAN; HYPOTHALAMUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; RISK ASSESSMENT; RISK REDUCTION; SITTING; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; LIFE STYLE; MOTOR ACTIVITY; OBESITY; OVERWEIGHT; PREDIABETIC STATE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 42649129395     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(07)80027-5     Document Type: Article

References (86)

1. Hossain P., Kawar B., and El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 356 (2007) 213-215
2. Haffner S. Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes. Eur Heart J Suppl 8 Suppl B (2006) B20-B25
3. Klein S., Allison D., Heymsfield S., et al. Waist circumference and cardiometabolic risk: A consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 30 (2007) 1647-1652
4. See R., Abdullah S., McGuire D., et al. The association of differing measures of overweight and obesity with prevalent atherosclerosis: The Dallas Heart Study. J Am Coll Cardiol 50 (2007) 752-759
5. Carroll M., Lacher D., Sorlie P., et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 294 (2005) 1773-1781
6. Eaton C. Hyperlipidemia. Prim Care 32 (2005) 1027-1055
7. Safford M., Eaton L., Hawley G., et al. Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med 163 (2003) 922-928
8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2493
9. Grundy S., Cleeman J., Bairey C., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
10. Simons L., Levis G., and Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 164 (1996) 208-211
11. Avramoglu R., Basciano H., and Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 368 (2006) 1-19
12. Boyle J., Honeycutt A., Narayan K., et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 24 (2001) 1936-1940
13. Glaser N., and Jones K. Non-insulin dependent diabetes mellitus in Mexican-American children. West J Med 168 (1998) 11-16
14. Grandinetti A., Chang H., Mau M., et al. Prevalence of glucose intolerance among Native Hawaiians in two rural communities. Native Hawaiian Health Research (NHHR) Project. Diabetes Care 21 (1998) 549-554
15. American Association of Physicians of Indian Origin. Diabetes in South Asians
16. http://www.aapimsr.org/Diabetes/diabetesfacts.htm Accessed October 8, 2007
17. Knowler S., Bennett P., Hamman R., and Miller M. Diabetes incidence and prevalence in Pima Indians: A 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 108 (1978) 497-505
18. Hogan P., Dall T., and Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
19. Denke M., Sempos C., and Grundy S. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med 153 (1993) 1093-1103
20. Fox C., Massaro J., Hoffmann U., et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation 116 (2007) 39-48
21. Lemieux I., Pascot A., Couillard C., et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 102 (2000) 179-184
22. LaMonte M., Ainsworth B., DuBose K., et al. The hypertriglyceridemic waist phenotype among women. Atherosclerosis 171 (2003) 123-130
23. Esmaillzadeh A., Mirmiran P., and Azizi F. Clustering of metabolic abnormalities in adolescents with the hypertriglyceridemic waist phenotype. Am J Clin Nutr 83 (2006) 36-46
24. Couillard C., Bergeron N., Prud'homme D., et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 47 (1998) 953-960
25. Alipour A., Elte J., van Zaanen H., et al. Postprandial inflammation and endothelial dysfunction. Biochem Soc Trans 35 (2007) 466-469
26. Patsch J., Miesenbock G., Hopferwieser T., et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12 (1992) 1336-1345
27. Boquist S., Ruotolo G., Tang R., et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 100 (1999) 723-728
28. Lupattelli G., Pasqualini L., Siepi D., et al. Increased postprandial lipemia in patients with normolipemic peripheral arterial disease. Am Heart J 143 (2002) 733-738
29. Blackburn P., Lamarche B., Couillard C., et al. Postprandial hyperlipidemia: Another correlate of the "hypertriglyceridemic waist" phenotype in men. Atherosclerosis 171 (2003) 327-336
30. Steinberger J., Moorehead C., Katch V., and Rocchini A. Relationship between insulin resistance and abnormal lipid profile in obese adolescents. J Pediatr 126 (1995) 690-695
31. Perez-Mendez O., Torres-Tamayo M., Posadas-Romero C., et al. Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. Clin Chim Acta 376 (2007) 17-22
32. Unwin N., Harland J., White M., et al. Body mass index, waist circumference, waist-hip ratio, and glucose intolerance in Chinese and Europid adults in Newcastle, UK. J Epidemiol Community Health 51 (1997) 160-166
33. Lovegrove J., Brady L., Lesauvage S., et al. Lack of association between central adiposity and lipaemia in UK Sikh men. Int J Obes Relat Metab Disord 27 (2003) 1373-1382
34. Jafar T., Chaturvedi N., and Pappas G. Prevalence of overweight and obesity and their association with hypertension and diabetes mellitus in an Indo-Asian population. CMAJ 175 (2006) 1071-1077
35. Razak F., Anand S., Shannon H., et al. Defining obesity cut points in a multiethnic population. Circulation 115 (2007) 2111-2118
36. International Diabetes Federation. Care and Education. IDF Metabolic Syndrome Definition. The IDF Consensus Worldwide Definition of the Metabolic Syndrome
37. www.idf.org Accessed September 25, 2007
38. Dandona P., and Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 90 (2002) 27G-33G
39. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
40. Twigg S., Kamp M., Davis T., et al. Prediabetes: A position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 186 (2007) 461-465
41. Tuomilehto J., Lindstrom J., Eriksson J., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
42. Pan X., Li G., Hu Y., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544
43. Shaw J., Zimmet P., de Courten M., et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?. Diabetes Care 22 (1999) 399-402
44. Coutinho M., Gerstein H., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999) 233-240
45. Liao D., Shofer J., Boyko E., et al. Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diabetes Care 24 (2001) 39-44
46. Barr E., Zimmet P., Welborn T., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116 (2007) 151-157
47. Ekelund U., Brage S., Franks P., et al. Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians: The Medical Research Council Ely Study. Diabetes Care 28 (2005) 1195-1200
48. Brage S., Wedderkopp N., Ekelund U., et al. Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children: The European Youth Heart Study (EYHS). Diabetes Care 27 (2004) 2141-2148
49. Dunstan D., Salmon J., Healy G., et al. Association of television viewing with fasting and 2-h postchallenge plasma glucose levels in adults without diagnosed diabetes. Diabetes Care 30 (2007) 516-522
50. Healy G., Dunstan D., Salmon J., et al. Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose. Diabetes Care 30 (2007) 1384-1389
51. Larson-Meyer D., Heilbronn L., Redman L., et al. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 29 (2006) 1337-1344
52. Ross R., Dagnone D., Jones P., et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 133 (2000) 92-103
53. Gardner C., Kiazand A., Alhassan S., et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: The A TO Z Weight Loss Study: A randomized trial. JAMA 297 (2007) 969-977
54. Atkins R. Dr. Atkins' New Diet Revolution (2002), Harper Collins, New York, NY
55. Sears B., and Lawren W. Enter the Zone (1995), Harper Collins, New York, NY
56. Brownell K. The LEARN Manual for Weight Management (2000), American Health Publishing Co, Dallas, Tex
57. Ornish D. Eat More, Weigh Less (2001), Harper Collins, New York, NY
58. McMillan-Price J., Petocz P., Atkinson F., et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: A randomized controlled trial. Arch Intern Med 166 (2006) 1466-1475
59. Ebbeling C., Leidig M., Feldman H., et al. Effects of a low-glycemic load vs low-fat diet in obese young adults: A randomized trial. JAMA 297 (2007) 2092-2102
60. Nordmann A., Nordmann A., Briel M., et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: A meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 285-293
61. Goralski K., and Sinal C. Type 2 diabetes and cardiovascular disease: Getting to the fat of the matter. Can J Physiol Pharmacol 85 (2007) 113-132
62. Dandona P., Aljada A., and Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 25 (2004) 4-7
63. Fantuzzi G., and Mazzone T. Adipose tissue and atherosclerosis: Exploring the connection. Arterioscler Thromb Vasc Biol 27 (2007) 996-1003
64. Knowler W., Barrett-Connor E., Fowler S., et al., for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
65. Chiasson J., Josse R., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
66. Gerstein H., Yusuf S., Bosch J., et al., for the DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368 (2006) 1096-1105
67. Rao S., Disraeli P., and McGregor T. Impaired glucose tolerance and impaired fasting glucose. Am Fam Physician 69 (2004) 1961-1968
68. Lindstrom J., Louheranta A., Mannelin M., et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26 (2003) 3230-3236
69. Olefsky J., and Saltiel A. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11 (2000) 362-368
70. Del Prato S., and Marchetti P. Targeting insulin resistance and beta-cell dysfunction: The role of thiazolidinediones. Diabetes Technol Ther 6 (2004) 719-731
71. Tankova T. Current indications for metformin therapy. Rom J Intern Med 41 (2003) 215-225
72. Gelfand E., and Cannon C. Rimonabant: A cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 47 (2006) 1919-1926
73. Bensaid M., Gary-Bobo M., Esclangon A., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
74. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8 (2005) 585-589
75. Pagotto U., Vicennati V., and Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 37 (2005) 270-275
76. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 (2003) 671-674
77. Carr M., and Brunzell J. Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89 (2004) 2601-2607
78. Kershaw E., and Flier J. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 (2004) 2548-2556
79. Liu Y., Connoley I., Wilson C., and Stock M. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29 (2005) 183-187
80. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
81. Bluher M., Engeli S., Kloting N., et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55 (2006) 3053-3060
82. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med 120 (2007) S18-S28
83. Despres J., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
84. Van Gaal L., Rissanen A., Scheen A., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
85. Pi-Sunyer F., Aronne L., Heshmati H., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 295 (2006) 761-775
86. Scheen A., Finer N., Hollander P., et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 368 (2006) 1660-1672